

# Rapid clinical translation of synthetic lethal drug combinations

2012:  
publication BRAF-EGFR synthetic lethal  
interaction

2014:  
Phase 1b study completed  
*First patient in trial*  
*8 months post publication*

2019:  
Validated in BEACON phase III trial



2020:  
FDA approval BRAF+EGFR combination

## LETTER

doi:10.1038/nature10868

### Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Anirudh Prahallad<sup>1</sup>\*, Chong Sun<sup>1</sup>\*, Sidong Huang<sup>1</sup>\*, Federica Di Nicolantonio<sup>2,3</sup>\*, Ramon Salazar<sup>4</sup>, Davide Zecchin<sup>2</sup>, Roderick L. Beijersbergen<sup>1</sup>, Alberto Bardelli<sup>2,3</sup> & René Bernards<sup>1</sup>



The NEW ENGLAND JOURNAL of MEDICINE

## ORIGINAL ARTICLE

### Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

S. Kopetz, A. Grothey, R. Yaeger, E. Van Cutsem, J. Desai, T. Yoshino, H. Wasan, F. Ciardiello, F. Loupakis, Y.S. Hong, N. Steeghs, T.K. Guren, H.-T. Arkenau, P. Garcia-Alfonso, P. Pfeiffer, S. Orlov, S. Lonardi, E. Elez, T.-W. Kim, J.H.M. Schellens, C. Guo, A. Krishnan, J. Dekervel, V. Morris, A. Calvo Ferrandiz, L.S. Tarpgaard, M. Braun, A. Gollerkeri, C. Keir, K. Maharry, M. Pickard, J. Christy-Bittel, L. Anderson, V. Sandor, and J. Tabernero

### U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy